{"url_path":"/sec/espr/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","accession_number":"0001628280-26-032870","cik":"0001434868","ticker":"ESPR","issuer_name":"Esperion Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","primary_entity_key":"0001434868","primary_entity_name":"Esperion Therapeutics, Inc."},"word_count":88,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings\n\nThe information required with respect to this item can be found under “Commitments and Contingencies” in Note 5 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference into this Item 1.\n\nIn the future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows."}